Preclinical efficacy of ALG-097558 in SARS-CoV-2 hamster model presented

May 17, 2023

Researchers from Aligos Therapeutics Inc. and the Katholieke Universiteit Leuven reported on the preclinical activity of ALG-097558, a novel oral available 3CL protease inhibitor with pan-coronavirus antiviral activity.

BioWorld Science Conferences Infection Coronavirus

Today's news in brief

BioWorld

BioWorld briefs for April 1, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 1, 2025.

Novo Nordisk licenses Lexicon’s preclinical obesity drug in $1B deal

BioWorld Science

As companies continually search for next-generation obesity prospects, one of the leaders in the disease space, Novo Nordisk A/S, has obtained an exclusive...

Corcept looks to NDA following strong phase III ovarian cancer data

BioWorld

Relacorilant, a cortisol modulator from Corcept Therapeutics Inc., produced new and strong phase III results in treating platinum-resistant ovarian cancer. The...

Otsuka submits first BLA to FDA for sibeprenlimab in IgAN

BioWorld

Otsuka Pharmaceutical Development & Commercialization Inc. filed its BLA with the U.S. FDA for sibeprenlimab to treat immunoglobulin A nephropathy (IgAN). The...